Compare INFQ & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INFQ | SUPN |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | 205 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 2026 | 2010 |
| Metric | INFQ | SUPN |
|---|---|---|
| Price | $10.35 | $47.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $20.00 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 15.0M | 950.3K |
| Earning Date | N/A | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $25.46 | $22.70 |
| Revenue Next Year | $25.00 | $19.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.52 | $32.21 |
| 52 Week High | $21.28 | $59.68 |
| Indicator | INFQ | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 36.01 | 51.25 |
| Support Level | $8.54 | $43.43 |
| Resistance Level | $12.22 | $52.36 |
| Average True Range (ATR) | 1.16 | 1.60 |
| MACD | -0.30 | 0.34 |
| Stochastic Oscillator | 0.48 | 42.55 |
Infleqtion Inc developing and commercializing quantum technology products as part of a full-stack platform, which currently includes offerings such as quantum sensing, quantum computing, and software. Its quantum-enabled solutions are focused on addressing the world's pressing challenges, with technologies actively deployed across some sectors today, including defense and security, artificial intelligence (AI), energy optimization, space and frontier, materials discovery, and cybersecurity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.